Insider Stock Sales Create Ripples for BridgeBio Investors BridgeBio Pharma's recent insider stock sales, including CEO Neil Kumar's $2.52 million transaction, have drawn attention amidst the company's strong market performance. Despite a 9% weekly decline, the stock remains up 34% over six months, supported by robust sales of its drug Attruby and promising financial strategies.34